Clinical Trials
13
Active:2
Completed:8
Trial Phases
2 Phases
Phase 3:3
Not Applicable:10
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials
Not Applicable
10 (76.9%)Phase 3
3 (23.1%)Evolution of Functional Gastrointestinal Disorders in Infants Fed With a New Infant Formula
Not Applicable
Recruiting
- Conditions
- Functional Gastrointestinal Disorders
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- United Pharmaceuticals
- Target Recruit Count
- 139
- Registration Number
- NCT06488274
- Locations
- 🇫🇷
Site 02, Nice, France
🇫🇷Site 04, Paris, France
🇫🇷Site 03, Toulon, France
Evaluation of Tolerance, Efficacy and Safety of an Hydrolyzed Formula in Infants With IgE/Non-IgE Mediated CMA.
Not Applicable
Active, not recruiting
- Conditions
- Cow's Milk Allergy
- First Posted Date
- 2024-07-01
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- United Pharmaceuticals
- Target Recruit Count
- 70
- Registration Number
- NCT06481280
- Locations
- 🇧🇪
Private practice Elena BRADATAN, Namur, Begium, Belgium
🇮🇹University Hospital - Umberto I Sapienza, Roma, Italy
Evaluation of the Efficacy of a New Specific Infant Formula in Case of Functional Constipation
Not Applicable
Recruiting
- Conditions
- Functional Constipation
- First Posted Date
- 2022-04-22
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- United Pharmaceuticals
- Target Recruit Count
- 80
- Registration Number
- NCT05340712
- Locations
- 🇮🇹
University of Naples "Federico II", Napoli, Italy
🇮🇹University of Campania Luigi Vanvitelli, Napoli, Italy
Evaluation of an Adapted Formula on Atopic Dermatitis.
Not Applicable
Active, not recruiting
- Conditions
- Atopic Dermatitis
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- United Pharmaceuticals
- Target Recruit Count
- 126
- Registration Number
- NCT05318300
- Locations
- 🇧🇪
Center_13, Namur, Belgium
🇧🇪Center_14, Thuin, Belgium
🇫🇷Center_05, Nice, France
Study on the Efficacy and Tolerance of a New Anti-regurgitation Infant Formula (STELLAR)
Not Applicable
- Conditions
- Gastroesophageal Reflux in Children
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2020-04-24
- Lead Sponsor
- United Pharmaceuticals
- Target Recruit Count
- 346
- Registration Number
- NCT04358146
- Prev
- 1
- 2
- 3
- Next
News
No news found